Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ScienceDirect Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks Eloralintide supplier 2883634 40 8 Peptide synthesis In early studies, a new drug under investigation called eloralintide helped some adults lose nearly 50 pounds in under a year and it's not a GLP 1: https: bit.ly 43nPJnS